NCT01815333View on ClinicalTrials.gov

Clinical and Technical Feasibility of a Ultrasuperparamagnetic Nanoparticle Iron Oxide (USPIO)-Enhanced Magnetic Resonance Lymph Node Imaging

NACompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

July 25, 2019

Study Completion Date

July 25, 2019

Conditions
Cancer of Lymph Node
Interventions
DRUG

Feraheme

6 mg of iron/kg (maximum 510 mg/dose) injected at a rate of 1 ml/sec (30 mg/sec) or slower after initial MRI.

PROCEDURE

Magnetic Resonance Imaging (MRI)

MRI scan performed before Feraheme injection. After Feraheme injection, MRI scan performed 2 days later, and then again the following day.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT01815333 - Clinical and Technical Feasibility of a Ultrasuperparamagnetic Nanoparticle Iron Oxide (USPIO)-Enhanced Magnetic Resonance Lymph Node Imaging | Biotech Hunter | Biotech Hunter